Shockwave Medical Inc. news

• EMPOWER CAD is the First Prospective, Female-Only Study of Coronary Interventions
• Study Seeks to Confirm Benefits of Shockwave’s Coronary IVL in Females Who Historically Have Suffered Less Favorable Clinical Outcomes than Male Patients with Traditional Therapies

Shockwave Medical, Inc. (NASDAQ: SWAV), a pioneer in the development of Intravascular Lithotrips

In a release issued under the same headline on August 26, 2022, by Shockwave Medical, Inc. (NASDAQ: SWAV), please note that the fireside chat time for the Wells Fargo Healthcare Conference has been updated. The correct presentation time is 9:10 am Eastern Time. The details for the Morgan Stanley Healthcare Conference remain the same.

The corrected release appears below:

Shockwave Medical, Inc. (NASDAQ: SWAV), a pioneer in the development of Intravascular Lithotripsy (IVL)

Shockwave Medical, Inc. (NASDAQ: SWAV), a pioneer in the development of Intravascular Lithotripsy (IVL) to treat severely calcified cardiovascular disease, announced today that the company will be participating in two upcoming virtual investor conferences:

• The 2022 Wells Fargo Healthcare Conference
  Fireside Chat on Thursday, September 8, 2022, at 9:45 a.m. Eastern Time.
• The Morgan Stanley 20th Annual Global Healthcare Conference
  Fireside Chat on Tuesday, Sep

Shockwave Medical, Inc. (NASDAQ: SWAV), a pioneer in the development of Intravascular Lithotripsy (IVL) to treat severely calcified cardiovascular disease, and Genesis MedTech Group announced today that they have successfully obtained approval from China’s National Medical Products Administration (NMPA) to market and sell the Shockwave IVL System with the Shockwave C² Coronary IVL Catheters and the Shockwave M⁵ and S⁴<

Shockwave Medical, Inc. (NASDAQ: SWAV), a pioneer in the development of Intravascular Lithotripsy (IVL) to treat severely calcified cardiovascular disease, announced today new data confirming excellent one-year outcomes with coronary IVL in both women and men. The one-year results from the Disrupt CAD clinical program were presented at the 2022 Scientific Sessions of the Society for Cardiovascular Angiography & Interventions (SCAI).

Unlike previous reports with atherectomy that ha